We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

29 hedge funds and large institutions have $706K invested in Navidea Biopharmaceuticals Inc. in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more call options, than puts

Call options by funds: $60K | Put options by funds: $16K

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

4% more funds holding

Funds holding: 28 → 29 (+1)

9% less capital invested

Capital invested by funds: $772K → $706K (-$66.4K)

Holders
29
Holders Change
+1
Holders Change %
+3.57%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
3
Closed
3
Calls
$60K
Puts
$16K
Net Calls
+$44K
Net Calls Change
+$16K

Top Buyers

Rank Fund Capital Flow
1
FIA
FNY Investment Advisers
New York
+$220K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$214K
3
Citadel Advisors
Citadel Advisors
Florida
+$31K
4
Wolverine Trading
Wolverine Trading
Illinois
+$19.2K
5
Victory Capital Management
Victory Capital Management
Texas
+$5.3K

Top Sellers

Rank Fund Capital Flow
1
Group One Trading
Group One Trading
Illinois
-$32.9K
2
JP Morgan Chase
JP Morgan Chase
New York
-$6.57K
3
ACM
Allred Capital Management
Texas
-$3.97K
4
Morgan Stanley
Morgan Stanley
New York
-$110
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
26
Parallel Advisors
California
– +$386 +350 New
1
2

NAVB Hedge Fund Activity: Q1 2020 in Review

29 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2020, worth a combined $706K — down 8.6% from $772K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new NAVB positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 3 trimmed.

The largest buyer was FNY Investment Advisers, opening a new position worth an estimated $220K. The largest seller was Group One Trading, exiting entirely with an estimated $32.9K sold.

  • 29 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2020, up from 28 in Q4 2019.
  • Funds reported $706K of Navidea Biopharmaceuticals Inc. stock for Q1 2020, down 8.6% quarter-over-quarter.
  • 6 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2020 and 3 closed out, a net change of +3 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2020 was FNY Investment Advisers, an estimated $220K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2020 was Group One Trading, an estimated $32.9K sold.

Based on aggregated 13F filings for Q1 2020.